A case with diabetes mellitus associated with growth hormone (GH)-producing pituitary adenomais described. A 56-year-old womanwho had been treated for diabetes mellitus for 3 years, was admitted for the treatment of hyperglycemia. She showeda few acromegalic features and her plasma GHlevel was 146+16 ng/ml. After improvement of plasma glucose level by insulin injection, octreotide therapy (100 jag/8 hours) was started. Seven days after the initiation of octreotide therapy, the fasting plasma glucose level was almost normalized without insulin injection. After the octreotide treatment, urinary C-peptide excretion was significantly decreased and the plasma GH level became within normal range. In this case, octreotide appears to have improved the insulin sensitivity by reducing the plasma GHlevel.
Introduction
Glucoseintolerance, one of the major complications of acromegaly, is a result of long-standing over-production of growth hormone (GH). It has been reported that 29% to 45% of acromegalic patients have insulin resistance and/or glucose intolerance and 10% to 20% have overt diabetes mellitus (1 , 2) . Octreotide is a long-acting somatostatin analogue which has been shown to be effective in the treatment of acromegaly (3) (4) (5) (6) (7) (8) (9) (10) . It remains controversial whether or not octreotide is applicable for acromegalics whohave glucose intolerance, because somereports have shownthat octreotide worsensthe glucose tolerance (4, 8, 1 1-1 3). We report here the dramatical improvement of hyperglycemia with octreotide treatment observed in a patient with GH-producing pituitary adenoma.
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Case Report
A housewife was diagnosed as diabetes mellitus at the age of 53 years old, and was started on diet therapy and sulfonil urea therapy. The plasma glucose level continued to increase gradually even after high dose glibenclamide (10 mg/day) and she was admitted to our hospital at age of 56. The patient had been a full-term infant born after an uneventful pregnancy. No perinatal problem was noted. Her regular menstruation finished at age 49. Her family history was not significant for diabetes mellitus or hypertension. On examination her blood pressure was 108/72 mmHgand pulse rate was 66/min regular. No abnormal neurological finding was observed. The patient showed a few acromegalic features; her lower lip was slightly enlarged and the interteeth spaces were wide. Heel pad thickness was 28 mmby radiological examination. Both body weight and body heighthadbeen stable in theprevious 3 years (43.5 kg and 153.8 cmrespectively). Diabetic retinopathy was not observed. Laboratory data on admission are shown in Table 1 basal plasma GH (136 ng/ml) was remarkably elevated and the urinary secretion of GH(82.1 ng/day) was increased. Plasma somatomedin-C (Sm-C) (594 ng/ml) was also elevated. The response of insulin secretion to oral 75g glucose loading was impaired (Table 3) . Plasma GHwas not suppressed by oral 75g
glucose loading and increased paradoxically in response to intravenous thyrotropin releasing hormone (TRH) injection (Table 3) . These results indicate that a high level of GHwas secreted from tumorous tissues. No paradoxical response ofGH was observed when luteinizing hormone releasing hormone (LH-RH) was injected ( and FSHwere decreased and they did not increase in response to LH-RH (Table 3) . Free thyroxine and free triiodothyronine levels were slightly decreased, and the response of thyroid stimulating hormone (TSH) to TRHloading was blunted (Tables 2, 3). These results suggest that the secretion of gonadotropins and TSH was impaired. To lower the plasma glucose level, we started insulin therapy (Fig. 2) . When the dose was up to 22 U/day, the plasma glucose level before each meal reached 130-150 mg/dl. GH and Sm-C levels remained high. Eight days after the start of insulin treatment, we started subcutaneous injection of octreotide ( 1 00 jig/8 hours). After 7 days of injection of octreotide, plasma GH and Sm-Clevels and urinary secretion ofGH were decreased to normal (Table 4 , Fig. 2 ). Along with the octreotide treatment, the dose of insulin was gradually decreased from 22 units/day to 8 units/day (Fig. 2) . After seven days ofoctreotide treatment, insulin injection was no longer needed (Fig. 2 ). Serum Cpeptide level and urinary excretion of C-peptide gradually decreased after the octreotide treatment (Table 4 , Fig. 2 ), suggesting a decrease in insulin secretion from pancreatic (3-cells. These data indicate that insulin sensitivity was improved after the octreotide injection. After two weeks' octreotide treatment, transsphenoidal surgery for pituitary adenomawas performed. After the operation, plasma GHand Sm-Clevels were normalized. Fasting levels of plasma glucose and Cpeptide were 124 mg/dl and 1.9 ng/ml respectively. Seventyfive gram oral glucose tolerance test revealed that the patient no longer had diabetes mellitus but impaired glucose tolerance (Table 5) . Response of insulin secretion to oral 75g glucose loading was almost unchanged compared with that before the operation (Table 5) .
Discussion
In the present patient, the somatostatin analogue, octreotide, showed a remarkable effect on the improvement of hyperglycemia in a diabetic patient with GH-producing pituitary adenoma. Continuous injection of octreotide facilitated the patient to be free from insulin therapy and to lower plasma glucose levels. Amongseveral studies concerning the effect of octreotide on insulin resistance and glucose tolerance, there are few reports on the remarkableimprovement of hyperglycemia by octreotide in acromegalic patients (14, 15) . In acromegaly, glucose intolerance is characterized by defects in the ability of insulin to suppress hepatic glucose production and to stimulate peripheral glucose utilization ( 1 6).
As somatostatin inhibits secretion of insulin from pancreatic (3-cells, the concern that octreotide maydeteriorate the glucose tolerance is raised. In this relation, in a report of the 55 acromegalic patients who had normal glucose tolerance, 20% diabetes, respectively, after treatment with octreotide (1 1). Conversely, of 1 1 patients whowere diabetic at baseline three becamenormal or impaired glucose tolerance after octreotide therapy. There was no relationship between the dose ofoctreotide and change in glycemic state (1 1). Another study reported that glucose tolerance was unchanged or improved in 52%and declined in 48%of 25 patients who had long-term treatment of octreotide (4) . Several pertinent studies which have been reported are summarized in Table 6 . Thus, the effect ofoctreotide on glucose tolerance may vary with individuals.
The major reason for the variable effects of octreotide on glucose tolerance may be due to the multiple complex effects of this analogue on several factors affecting glucose metabolism (Table 7) . Octreotide inhibits GHand insulin-like growth factor I (IGF-I) hypersecretion in acromegalic patients. Inhibition of GHeffects leads to stimulation of gluconeogenesis in hepatocytes, impairment of tissue glucose uptake, and a decrease in insulin receptor sensitivity and post-receptor insulin action. Octreotide also inhibits the secretion of insulin, glucagon, and other intestinal hormones. Furthermore, it has been reported that this analogue increases IGF binding protein 1 concentration, which is knownto counteract the insulin-like effect of IGF-I (18, 19). Octreotide also has an effect to delay gastrointestinal movementwhich leads to the decrease or delay of glucose absorption. These combined effects of octreotide on carbohydrate metabolismmight be expected to be the reason for the unpredictable effect of this analogue on glucose tolerance in acromegalic patients.
In the present case, octreotide showedcomplete normalization of the plasma GHlevel and moderate inhibition of insulin secretion, which means that octreotide inhibited GHsecretion moreeffectively than insulin secretion. Unfortunately, other hormonal or digestive effects of octreotide (including plasma glucagon level) were not precisely examined. But we expect that the remarkable improvement of plasma glucose by octreotide was mainly due to complete normalization of the plasma GH level. Wealso expect that she was not originally diabetic before her plasma GHbecame high level. This factor and the lack of obesity mayhelp to attain the remarkable effect of octreotide.
Another unique possibility is variance of concentrations of "diabetogenic GH" in patients' sera. Human GH(hGH)-(44-191) which lacks N-terminal amino acids has been reported to be ten times more potent than intact hGHin causing glucose intolerance in an animal model (20) and has been proven to circulate in human blood (2 1 ). The relationship between plasma hGH-(44-191) concentrations and the severity of diabetes in acromegalics has not been examined. Further studies are necessary to elucidate the clinical significance of the diabetogenic GH in acromegalic patients with overt diabetes which are improved by octreotide treatment.
In conclusion, we report a case in which octreotide dramatically improved hyperglycemia associated with GH-producing pituitary adenoma.This seems to be caused by the remarkable improvementof insulin resistance associated with GHexcess.
